KALA BIO Implements 1-for-50 Reverse Stock Split, Reducing Outstanding Shares from 929.5 Million to 18.6 Million
KALA BIO executed a 1-for-50 reverse stock split to meet Nasdaq listing requirements and consolidate its capital structure, effective May 11, 2026.
KALA BIO, Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company building an on-premises AI infrastructure platform for the biotechnology industry, announced the implementation of a 1-for-50 reverse stock split of its common stock. The reverse stock split became effective at 4:05 p.m. Eastern Time on May 8, 2026, and split-adjusted trading is set to begin on the Nasdaq Capital Market at the market open on May 11, 2026.
The reverse stock split reduces the company's outstanding common shares from approximately 929.5 million to approximately 18.6 million. Cash payments will be issued in lieu of fractional shares, and proportional adjustments will be made to outstanding equity awards, warrants, and other convertible securities. This move is often undertaken by companies to increase their stock price to meet minimum bid price requirements for continued listing on stock exchanges like Nasdaq.
KALA BIO is a clinical-stage biopharmaceutical company with a dual strategy. The company combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business. This platform is designed to deploy secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments. Through an exclusive worldwide license for the Researgency AI research platform from Younet, Kala aims to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations to unlock the value of their proprietary biological data without surrendering control.
The company is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. Kala's focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector. For more information about the company, visit https://www.researgency.ai/.
The reverse stock split is a significant corporate action that affects shareholders by consolidating the number of shares they hold while increasing the per-share price. This can impact liquidity and investor perception. For KALA BIO, the move may help the company maintain its listing on the Nasdaq Capital Market and potentially attract a broader range of institutional investors who may have minimum price requirements for their portfolios. The full press release is available at https://ibn.fm/yUznR.